경구 생물제제 시장(2026-2030년)

The global oral biologics market is forecasted to grow by USD 11132.2 mn during 2025-2030, accelerating at a CAGR of 21.1% during the forecast period. The report on the global oral biologics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by technological innovations in drug delivery systems and encapsulation protocols, high patient demand for non-invasive therapies in chronic disease management, escalating strategic alliances, licensing deals, and venture investments.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global oral biologics market is segmented as below:

By Type

• GLP-1 receptor agonists
• Hormones
• Recombinant enzymes
• Somatostatin analogues
• Others

By Product Type

• Tablets
• Capsules
• Syrups
• Oral powders
• Others

By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Online pharmacies

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Russia
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the technological breakthroughs in oral drug delivery systems and advanced bioavailability formulations as one of the prime reasons driving the global oral biologics market growth during the next few years. Also, rising global prevalence of chronic diseases and demand for patient-centric oral therapies and strategic alliances, robust clinical pipelines, and favorable regulatory support will lead to sizable demand in the market.

The report on the global oral biologics market covers the following areas:

• Global oral biologics market sizing
• Global oral biologics market forecast
• Global oral biologics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global oral biologics market vendors that include AbbVie Inc., Astellas Pharma Inc., AstraZeneca Plc, Bachem AG, Bausch Health Co Inc., Biocatalysts Ltd., Catalent Inc., Colorcon Inc., Corden Pharma Intl. GmbH, Evonik Industries AG, Ironwood Pharmaceuticals Inc., Lonza Group Ltd., Nestle Health Science S.A., Novo Nordisk AS, Novozymes AS, PolyPeptide Group, Roquette Freres SA, Viatris Inc., VIVUS LLC. Also, the global oral biologics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Product Type
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Oral Biologics Market 2020 - 2024
  • Historic Market Size - Data Table on Global Oral Biologics Market 2020 - 2024 ($ million)
• 5.2 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
• 5.3 Product Type segment analysis 2020 - 2024
  • Historic Market Size - Product Type Segment 2020 - 2024 ($ million)
• 5.4 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Oral Biologics Market
• 6.2 Impact of geopolitical conflicts on Global Oral Biologics Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Type

• 8.1 Market segments
• 8.2 Comparison by Type
• 8.3 GLP-1 receptor agonists - Market size and forecast 2025-2030
• 8.4 Hormones - Market size and forecast 2025-2030
• 8.5 Recombinant enzymes - Market size and forecast 2025-2030
• 8.6 Somatostatin analogues - Market size and forecast 2025-2030
• 8.7 Others - Market size and forecast 2025-2030
• 8.8 Market opportunity by Type
  • Market opportunity by Type ($ million)

9 Market Segmentation by Product Type

• 9.1 Market segments
• 9.2 Comparison by Product Type
• 9.3 Tablets - Market size and forecast 2025-2030
• 9.4 Capsules - Market size and forecast 2025-2030
• 9.5 Syrups - Market size and forecast 2025-2030
• 9.6 Oral powders - Market size and forecast 2025-2030
• 9.7 Others - Market size and forecast 2025-2030
• 9.8 Market opportunity by Product Type
  • Market opportunity by Product Type ($ million)

10 Market Segmentation by Distribution Channel

• 10.1 Market segments
• 10.2 Comparison by Distribution Channel
• 10.3 Retail pharmacies - Market size and forecast 2025-2030
• 10.4 Hospital pharmacies - Market size and forecast 2025-2030
• 10.5 Online pharmacies - Market size and forecast 2025-2030
• 10.6 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
  • 12.4.7 Russia - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Taiwan - Market size and forecast 2025-2030
  • 12.5.7 Singapore - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Australia - Market size and forecast 2025-2030
  • 12.6.2 UAE - Market size and forecast 2025-2030
  • 12.6.3 Brazil - Market size and forecast 2025-2030
  • 12.6.4 South Africa - Market size and forecast 2025-2030
  • 12.6.5 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.6 Turkey - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Technological innovations in drug delivery systems and encapsulation protocols
  • High patient demand for non-invasive therapies in chronic disease management
  • Escalating strategic alliances, licensing deals, and venture investments
• 13.2 Market challenges
  • Biological and enzymatic barriers to bioavailability in gastrointestinal tract
  • High manufacturing complexity and scalability constraints
  • Complex regulatory pathways and commercial pricing pressures
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Technological breakthroughs in oral drug delivery systems and advanced bioavailability formulations
  • Rising global prevalence of chronic diseases and demand for patient-centric oral therapies
  • Strategic alliances, robust clinical pipelines, and favorable regulatory support

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Business segments
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Segment focus
  • SWOT
• 15.5 Astellas Pharma Inc.
  • Astellas Pharma Inc. - Overview
  • Astellas Pharma Inc. - Product / Service
  • Astellas Pharma Inc. - Key news
  • Astellas Pharma Inc. - Key offerings
  • SWOT
• 15.6 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Business segments
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • AstraZeneca Plc - Segment focus
  • SWOT
• 15.7 Bachem AG
  • Bachem AG - Overview
  • Bachem AG - Business segments
  • Bachem AG - Key news
  • Bachem AG - Key offerings
  • Bachem AG - Segment focus
  • SWOT
• 15.8 Biocatalysts Ltd.
  • Biocatalysts Ltd. - Overview
  • Biocatalysts Ltd. - Product / Service
  • Biocatalysts Ltd. - Key offerings
  • SWOT
• 15.9 Catalent Inc.
  • Catalent Inc. - Overview
  • Catalent Inc. - Product / Service
  • Catalent Inc. - Key offerings
  • SWOT
• 15.10 Colorcon Inc.
  • Colorcon Inc. - Overview
  • Colorcon Inc. - Product / Service
  • Colorcon Inc. - Key offerings
  • SWOT
• 15.11 Corden Pharma Intl. GmbH
  • Corden Pharma Intl. GmbH - Overview
  • Corden Pharma Intl. GmbH - Product / Service
  • Corden Pharma Intl. GmbH - Key offerings
  • SWOT
• 15.12 Evonik Industries AG
  • Evonik Industries AG - Overview
  • Evonik Industries AG - Business segments
  • Evonik Industries AG - Key news
  • Evonik Industries AG - Key offerings
  • Evonik Industries AG - Segment focus
  • SWOT
• 15.13 Ironwood Pharmaceuticals Inc.
  • Ironwood Pharmaceuticals Inc. - Overview
  • Ironwood Pharmaceuticals Inc. - Product / Service
  • Ironwood Pharmaceuticals Inc. - Key offerings
  • SWOT
• 15.14 Lonza Group Ltd.
  • Lonza Group Ltd. - Overview
  • Lonza Group Ltd. - Business segments
  • Lonza Group Ltd. - Key news
  • Lonza Group Ltd. - Key offerings
  • Lonza Group Ltd. - Segment focus
  • SWOT
• 15.15 Novo Nordisk AS
  • Novo Nordisk AS - Overview
  • Novo Nordisk AS - Business segments
  • Novo Nordisk AS - Key offerings
  • Novo Nordisk AS - Segment focus
  • SWOT
• 15.16 Novozymes AS
  • Novozymes AS - Overview
  • Novozymes AS - Product / Service
  • Novozymes AS - Key offerings
  • SWOT
• 15.17 PolyPeptide Group
  • PolyPeptide Group - Overview
  • PolyPeptide Group - Product / Service
  • PolyPeptide Group - Key offerings
  • SWOT
• 15.18 Roquette Freres SA
  • Roquette Freres SA - Overview
  • Roquette Freres SA - Product / Service
  • Roquette Freres SA - Key offerings
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations